Aradigm Corporation today announced that the Company’s Investigational New Drug Application to conduct a pivotal Phase 3 clinical trial of Pulmaquin in non-cystic fibrosis bronchiectasis has been cleared by the U.S.
Zhejiang Jingxin Pharmaceutical Co., Ltd.
Top 100 Pharmaceutical Enterprises and the Listed Company SZ.002020